Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Non Operating Income: 2022-2025

Historic Non Operating Income for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $3.5 million.

  • Stoke Therapeutics' Non Operating Income fell 2.99% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 12.87%. This contributed to the annual value of $12.4 million for FY2024, which is 23.00% up from last year.
  • Stoke Therapeutics' Non Operating Income amounted to $3.5 million in Q3 2025, which was down 9.20% from $3.8 million recorded in Q2 2025.
  • Stoke Therapeutics' Non Operating Income's 5-year high stood at $3.8 million during Q2 2025, with a 5-year trough of $146,000 in Q1 2022.
  • Over the past 3 years, Stoke Therapeutics' median Non Operating Income value was $2.9 million (recorded in 2025), while the average stood at $3.0 million.
  • Per our database at Business Quant, Stoke Therapeutics' Non Operating Income soared by 1,369.18% in 2023 and then dropped by 6.85% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Non Operating Income (Quarterly) stood at $1.5 million in 2022, then soared by 72.78% to $2.6 million in 2023, then climbed by 20.66% to $3.2 million in 2024, then dropped by 2.99% to $3.5 million in 2025.
  • Its Non Operating Income stands at $3.5 million for Q3 2025, versus $3.8 million for Q2 2025 and $2.9 million for Q1 2025.